New Canadian research examines the safety of SGLT2 inhibitors in adults over 75, including kidney injury, hospitalization, and treatment risks.
Read More »New Canadian research examines the safety of SGLT2 inhibitors in adults over 75, including kidney injury, hospitalization, and treatment risks.
Read More »